MTN 015

Status:Ongoing
Phase:Other
Principal Investigator(s):Sharon A. Riddler
Objective:A long-term observational study that seeks to understand the nature of HIV progression and treatment response among women who acquired HIV while taking part in an MTN parent study of ARV-based prevention products. Results: MTN-015 was implemented initially at six African sites and enrolled 100/139 (72%) of eligible women who seroconverted in HIV Prevention Trials Network protocol 035 (HPTN 035, conducted by the MTN). The median time from seroconversion in HPTN 035 to enrollment in MTN-015 was 18 months.     Last updated May 10, 2021
Prevention Option(s):Microbicides
Study Design:
Results: Long-term follow-up of HIV seroconverters in microbicide trials - rationale, study design, and challenges in MTN-015.
Official Code: NCT00514098
Related Publications:
Clinical and Virologic Outcomes Following Initiation of Antiretroviral Therapy Among Seroconverters in the Microbicide Trials Network-020 Phase III Trial of the Dapivirine Vaginal Ring
HIV disease progression among women following seroconversion during a tenofovir-based HIV prevention trial
Trial Sponsors: MTN, NIAID (DAIDS-ES: 10529)
Start Date
End Date
August 25, 2008
June 30, 2019
Enrollment:0
Age range: ↔ any
Population:People Living with HIV